A Brief Review On Nanoparticles Drug Delivery System Used In Cervical Cancer

Year : 2025 | Volume : | : | Page : –
By
vector

Neha D. Patil,

vector

Divakar R. Patil,

vector

Akash S. Jain,

vector

Azam Z. Shaikh,

  1. B. Pharm. Student, Department of Pharmaceutics, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  2. Assistant Professor, Department of Pharmaceutics, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  3. Assistant Professor, Department of Quality Assurance, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  4. Principal, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_149202’);});Edit Abstract & Keyword

Among cervical tumor-related deaths worldwide, cervical cancer is a major cause. The limitations of traditional methods, such chemotherapy and radiation therapy, stem from their adverse effects and increased susceptibility to medications. Despite being seen as innovative options, immune checkpoint inhibitors (ICIs) have rather low clinical response rates. Reliable treatments for patients with metastatic or recurring cervical cancer are currently lacking. Lately, nanomaterials including as polymers, liposomes, and dendrimers have been identified as promising delivery vehicles due to their advantages in lower toxicity, enhanced biocompatibility, and tumor-specific administration. This article explores the applications of nanoparticles in cervical cancer treatment, drug delivery, and genome ed       iting utilizing CRISPR technology. Nanoparticles offer a versatile platform for addressing the challenges associated with cervical cancer therapies. By facilitating the precise delivery of therapeutic agents, nanoparticles can enhance the efficacy of treatments while minimizing off-target effects. These nanocarriers can encapsulate chemotherapeutic drugs, enabling controlled release and reducing systemic toxicity. Additionally, advancements in genome-editing technologies such as CRISPR-Cas9, when combined with nanoparticle-mediated delivery systems, open new avenues for targeting oncogenes and correcting genetic mutations associated with cervical cancer. Furthermore, functionalized nanoparticles can be engineered to exploit the tumor microenvironment, enhancing their accumulation at the tumor site and improving therapeutic outcomes. This innovative approach holds promise for overcoming current limitations and improving patient prognosis.

Keywords: immune checkpoint inhibitors , CRISPR-Cas9, cervical cancer , Human Papillomavirus , Oncoproteins

How to cite this article:
Neha D. Patil, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh. A Brief Review On Nanoparticles Drug Delivery System Used In Cervical Cancer. Research & Reviews : A Journal of Life Sciences. 2025; ():-.
How to cite this URL:
Neha D. Patil, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh. A Brief Review On Nanoparticles Drug Delivery System Used In Cervical Cancer. Research & Reviews : A Journal of Life Sciences. 2025; ():-. Available from: https://journals.stmjournals.com/rrjols/article=2025/view=0

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_149202’);});Edit

References

  1. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention [Internet]. World Health Organization; 2021 [cited 2025 Jan 15]. Available from: https://www.who.int/publications/i/item/97892400308
  2. Herrero and R. Murillo, “Cervical cancer,” in Cancer Epidemiology and Prevention, M. J. Thun, M. S. Linet, J. R. Cerhan, C. A. Haiman, and D. Schottenfeld, Eds., pp. 925–946, Oxford University Press, New York, NY, USA, 4th edition, 2018.
  3. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209– 249, 2021.
  4. D. Balasubramaniam, V. Balakrishnan, C. E. Oon, and G. Kaur, “Key molecular events in cervical cancer development,” Medicina, vol. 55, no. 7, p. 384, 2019.
  5. Doorbar, N. Egawa, H. Griffin, C. Kranjec, and I. Murakami, “Human papillomavirus molecular biology and disease association,” Reviews in Medical Virology, vol. 25, Suppl.1, pp. 2–23, 2015.
  6. De Villier EM, Fauquet C, Broker HU, et Classification of Papillomavirus. Virol. 2004;324:17–27.
  7. Pedroza-Saavedra A, Plett-Torres T, Chihu-Amparán L, Maldonado-Gama M, González-Jaimes A, Esquivel-Guadarrama F, Gutiérrez-Xicotencatl L. Molecular bases of human papillomavirus pathogenesis in the development of cervical cancer. Human Papillomavirus and Related Diseases—From Bench to Bedside—Research Aspects; Davy, V.-B., Ed. 2012 Jan 25:249-90.
  8. Gomez DT, Santos JL. Human papillomavirus infection and cervical cancer: pathogenesis and epidemiology. Communicating current research and educational topics and trends in applied microbiology. 2007;1:680-8
  9. Practice Bulletin No. 157: Cervical Cancer Screening and Prevention. (2016). Obstetrics and gynecology, 127(1), e1–e20. https://doi.org/10.1097/AOG.0000000000001263
  10. Mignani, S. el Kazzouli, M. Bousmina, and J. P. Majoral, “Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A concise overview,” Advanced Drug Delivery Reviews, vol. 65, no. 10, pp. 1316–1330, 2013.
  11. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nature reviews cancer. 2017 Jan;17(1):20-37.
  12. Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. Journal of controlled release. 2012 Apr 10;159(1):14-26.
  13. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. European Journal of Pharmaceutics and Biopharmaceutics. 2000 Jul 3;50(1):147-60.
  14. Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA, Bamias A. Systemic therapy in cervical cancer: 30 years in review. Critical reviews in oncology/hematology. 2019 May 1;137:9-17.
  15. Wang L, Liang TT. CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells. AMB Express. 2020 Mar 17;10(1):54.
  16. Ranghar S, Sirohi P, Verma P, Agarwal V. Nanoparticle-based drug delivery systems: promising approaches against infections. Brazilian Archives of Biology and Technology. 2014;57:209-22.
  17. Turos E, Shim JY, Wang Y, Greenhalgh K, Reddy GS, Dickey S, Lim DV. Antibiotic-conjugated polyacrylate nanoparticles: new opportunities for development of anti-MRSA agents. Bioorganic & medicinal chemistry letters. 2007 Jan 1;17(1):53-6.
  18. Banerjee SL, Khamrai M, Sarkar K, Singha NK, Kundu PP. Modified chitosan encapsulated core-shell Ag Nps for superior antimicrobial and anticancer activity. International journal of biological macromolecules. 2016 Apr 1;85:157-67.
  19. Yuan Y, Liu B. Self-assembled nanoparticles based on PEGylated conjugated polyelectrolyte and drug molecules for image-guided drug delivery and photodynamic therapy. ACS applied materials & interfaces. 2014 Sep 10;6(17):14903-10.
  20. Aggarwal U, Goyal AK, Rath G. Development of drug targeting and delivery in cervical cancer. Current Cancer Drug Targets. 2018 Oct 1;18(8):792-806.
  21. Svenningsen SW, Janaszewska A, Ficker M, Petersen JF, Klajnert-Maculewicz B, Christensen JB. Two for the price of one: PAMAM-dendrimers with mixed Phosphoryl choline and oligomeric poly (caprolactone) surfaces. Bioconjugate Chemistry. 2016 Jun 15;27(6):1547-57.
  22. Paris JL, Baeza A, Vallet-Regí M. Overcoming the stability, toxicity, and biodegradation challenges of tumor stimuli-responsive inorganic nanoparticles for delivery of cancer therapeutics. Expert opinion on drug delivery. 2019 Oct 3;16(10):1095-112.
  23. Cao W, He L, Cao W, Huang X, Jia K, Dai J. Recent progress of graphene oxide as a potential vaccine carrier and adjuvant. Acta biomaterialia. 2020 Aug 1;112:14-28.
  24. Di Santo R, Digiacomo L, Palchetti S, Palmieri V, Perini G, Pozzi D, Papi M, Caracciolo G. Microfluidic manufacturing of surface-functionalized graphene oxide nanoflakes for gene delivery. Nanoscale. 2019;11(6):2733-41.
  25. Xu M, Hu Y, Ding W, Li F, Lin J, Wu M, Wu J, Wen LP, Qiu B, Wei PF, Li P. Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance. Biomaterials. 2020 Nov 1;258:120308.
  26. Duo Y, Yang M, Du Z, Feng C, Xing C, Wu Y, Xie Z, Zhang F, Huang L, Zeng X, Chen H. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy. Acta Biomaterialia. 2018 Oct 1;79:317-30.
  27. Habibi N, Quevedo DF, Gregory JV, Lahann J. Emerging methods in therapeutics using multifunctional nanoparticles. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2020 Jul;12(4):e1625.
  28. Sahu NK, Gupta J, Bahadur D. PEGylated FePt–Fe 3 O 4 composite nanoassemblies (CNAs): in vitro hyperthermia, drug delivery and generation of reactive oxygen species (ROS). Dalton transactions. 2015;44(19):9103-13.
  29. Chong ZS, Wright GJ, Sharma S. Investigating cellular recognition using CRISPR/Cas9 genetic screening. Trends in Cell Biology. 2020 Aug 1;30(8):619-27.
  30. Chong ZS, Wright GJ, Sharma S. Investigating cellular recognition using CRISPR/Cas9 genetic screening. Trends in Cell Biology. 2020 Aug 1;30(8):619-27.
  31. Jiang C, Lin X, Zhao Z. Applications of CRISPR/Cas9 technology in the treatment of lung cancer. Trends in molecular medicine. 2019 Nov 1;25(11):1039-49.
  32. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018 Aug 31;361(6405):866-9.
  33. Zhou P, Liu W, Cheng Y, Qian D. Nanoparticle‐based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2021 Sep;13(5):e1718.
  34. Zhou X, Lian H, Li H, Fan M, Xu W, Jin Y. Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy. Frontiers in Pharmacology. 2022 Dec 16;13:1065793.
  35. Jin KT, Lu ZB, Chen JY, Liu YY, Lan HR, Dong HY, Yang F, Zhao YY, Chen XY. Recent trends in nanocarrier‐based targeted chemotherapy: selective delivery of anticancer drugs for effective lung, colon, cervical, and breast cancer treatment. Journal of Nanomaterials. 2020;2020(1):9184284.
  36. Zhou P, Liu W, Cheng Y, Qian D. Nanoparticle‐based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2021 Sep;13(5):e1718.
Ahead of Print Subscription Review Article
Volume
Received 17/12/2024
Accepted 12/01/2025
Published 18/01/2025
281